Samsung Biologics Co.,Ltd. (KRX: 207940)

Market Cap	76.30T
Revenue (ttm)	4.36T
Net Income (ttm)	1.05T
Shares Out	71.17M
EPS (ttm)	14,787.79
PE Ratio	72.49
Forward PE	60.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,539
Average Volume	81,062
Open	1,099,000
Previous Close	1,095,000
Day's Range	1,068,000 - 1,100,000
52-Week Range	721,000 - 1,113,000
Beta	0.31
RSI	63.18
Earnings Date	Jan 24, 2025

About Samsung Biologics

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality ass...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,744
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2023, Samsung Biologics's revenue was 3.69 trillion, an increase of 23.10% compared to the previous year's 3.00 trillion. Earnings were 857.69 billion, an increase of 7.47%.